Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | ERN1 | O75460 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29465715 | 0.89 | KCNH2 (0.62) | MAPTTDP1MEN1KMT2APOLB | |
| SCHEMBL1065088 | 0.89 | KCNH2 (0.62) | MAPTTDP1MEN1KMT2APOLB | |
| SCHEMBL11660607 | 0.83 | ERN1 (0.55) | MAPTTDP1MEN1KMT2APOLB | |
| SCHEMBL27861810 | 0.81 | ERN1 (0.53) | MAPTTDP1MEN1KMT2APOLB | |
| SCHEMBL1066145 | 0.81 | ERN1 (0.60) | MAPTMEN1KMT2AKCNH2ERN1 | |
| SCHEMBL11661845 | 0.79 | ERN1 (0.51) | MAPTTDP1MEN1KMT2AKCNH2 | |
| SCHEMBL29409289 | 0.79 | MAPT (1.00) | MAPTTDP1MEN1KMT2APOLB | |
| SCHEMBL737722 | 0.79 | MAPT (1.00) | MAPTTDP1MEN1KMT2APOLB | |
| SCHEMBL10945034 | 0.78 | ERN1 (0.50) | MAPTTDP1MEN1KMT2AKCNH2 | |
| SCHEMBL29600299 | 0.77 | PDE7A (0.47) | MAPTTDP1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114716354-B | Synthesis method of fenbendazole intermediate 2-nitro-4-thiophenylaniline | 山东国邦药业有限公司 | 2022-08-09 | — | — | CN | claimed |
| CN-114716354-A | Synthesis method of fenbendazole intermediate 2-nitro-4-thiophenyl aniline | 山东国邦药业有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-111499549-B | Method for preparing fenbendazole intermediate 2-nitro-4-thiophenyl aniline | 山东国邦药业有限公司 | 2022-04-22 | — | — | CN | claimed |
| CN-111349032-B | Preparation method of fenbendazole intermediate 2-nitro-4-thiophenyl aniline | 山东国邦药业有限公司 | 2021-08-06 | — | — | CN | claimed |
| CN-111499549-A | Method for preparing fenbendazole intermediate 2-nitro-4-thiophenyl aniline | 山东国邦药业有限公司 | 2020-08-07 | — | — | CN | claimed |
| CN-111349032-A | Preparation method of fenbendazole intermediate 2-nitro-4-thiophenyl aniline | 山东国邦药业有限公司 | 2020-06-30 | — | — | CN | claimed |
| CN-109467535-A | A kind of preparation method of Fenbendazole | 江苏宝众宝达药业有限公司 | 2019-03-15 | — | — | CN | claimed |
| CN-106397334-A | Preparation method of fenbendazole which is benzimidazole anti-helminthic drug | 江苏宝众宝达药业有限公司 | 2017-02-15 | — | — | CN | claimed |
| US-20250136570-A1 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4441033-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | Tango Therapeutics, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-118715206-A | Novel HDAC inhibitors and therapeutic uses thereof | 探戈医药股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20030158224-A1 | Quinolinone derivatives | CHIRON CORPORATION | 2003-08-21 | — | — | US | disclosed |
| US-6605617-B2 | Treating a patient in need of an inhibitor of vascular endothelial growth factor receptor tyrosine kinase | CHIRON CORPORATION | 2003-08-12 | — | — | US | disclosed |
| EP-1317442-A1 | QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20030028018-A1 | Quinolinone derivatives | CHIRON COPORATION | 2003-02-06 | — | — | US | disclosed |
| US-20020107392-A1 | Quinolinone derivatives | NOVARTIS AG (CH) | 2002-08-08 | — | — | US | disclosed |
| WO-2002022598-A1 | QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030028018-A1 | Quinolinone derivatives | SLCO1B1, SLCO1B3, SLCO1A2 | MAPT 2067/4885TDP1 1602/4885MEN1 992/4885 |
| US-20030158224-A1 | Quinolinone derivatives | SLCO1B1, SLCO1B3, SLCO1A2 | MAPT 2067/4885TDP1 1602/4885MEN1 992/4885 |
| US-20020107392-A1 | Quinolinone derivatives | SLCO1B1, SLCO1B3, SLCO1A2 | MAPT 2067/4885TDP1 1602/4885MEN1 992/4885 |
| US-20250136570-A1 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | HDAC1, HDAC7, HDAC5 | MAPT 2829/4885TDP1 846/4885MEN1 3551/4885 |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | HDAC1, HDAC7, HDAC5 | MAPT 2829/4885TDP1 846/4885MEN1 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.